← Patent-cliff monitor small molecule RYBELSUS SEMAGLUTIDE
Loss of exclusivity May 2034 latest FDA-listed patent expiry
Company NOVO NORDISK INC
Drug detail Brand name RYBELSUS Active ingredient SEMAGLUTIDE Strength 7MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2019 Marketing status RX
Listed patents Patent Expires Type 12514822 May 2034 use U-2628 12239739 May 2034 substance, product 10278923 May 2034 use U-2628 11033499 June 2033 product 11759501 March 2033 product 10933120 March 2033 product 11759503 March 2033 product 12594326 March 2033 product 11759502 March 2033 product 10960052 December 2031 product 10086047 December 2031 product 9278123 December 2031 product 11382957 December 2031 product 8129343 December 2031 substance, product 8536122 March 2026 substance, product
Regulatory exclusivity Code Expires I-976 October 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.